TRADES
Latest Trades
2978
results found
FUND
DATE
ACTION
TICKER
COMPANY
SHARES
% of ETF
ARKK 3 Feb 2022 Sell TRMB TRIMBLE INC 124,456 0.0710
ARKK 3 Feb 2022 Buy SQ BLOCK INC 234,583 0.1932
ARKK 3 Feb 2022 Buy SPOT SPOTIFY TECHNOLOGY SA 221,145 0.2856
ARKK 3 Feb 2022 Sell SKLZ SKILLZ INC 34,866 0.0010
ARKK 3 Feb 2022 Buy SE SEA LTD 6,789 0.0077
ARKK 3 Feb 2022 Sell IRDM IRIDIUM COMMUNICATIONS INC 506,754 0.1326
ARKK 3 Feb 2022 Sell EDIT EDITAS MEDICINE INC 1,597 0.0002
ARKK 3 Feb 2022 Sell DDD 3D SYSTEMS CORP 1,696 0.0002
ARKK 2 Feb 2022 Buy U UNITY SOFTWARE INC 26,161 0.0200
ARKK 2 Feb 2022 Sell TWTR TWITTER INC 511,106 0.1410
ARKK 2 Feb 2022 Buy TWLO TWILIO INC 20,156 0.0309
ARKK 2 Feb 2022 Buy TSLA TESLA INC 1,931 0.0132
ARKK 2 Feb 2022 Sell TRMB TRIMBLE INC 84,010 0.0461
ARKK 2 Feb 2022 Buy SQ BLOCK INC 361,862 0.3145
ARKK 2 Feb 2022 Buy SE SEA LTD 14,065 0.0160
ARKK 2 Feb 2022 Sell IRDM IRIDIUM COMMUNICATIONS INC 307,737 0.0792
ARKK 1 Feb 2022 Buy U UNITY SOFTWARE INC 48,470 0.0394
ARKK 1 Feb 2022 Buy TWLO TWILIO INC 26,936 0.0430
ARKK 1 Feb 2022 Buy TSLA TESLA INC 7,132 0.0502
ARKK 1 Feb 2022 Buy SQ BLOCK INC 22,713 0.0218
ARKK 1 Feb 2022 Sell SKLZ SKILLZ INC 3,114,813 0.1142
ARKK 1 Feb 2022 Buy SE SEA LTD 43,984 0.0515
ARKK 1 Feb 2022 Sell IRDM IRIDIUM COMMUNICATIONS INC 376,382 0.1022
ARKK 1 Feb 2022 Sell IOVA IOVANCE BIOTHERAPEUTICS INC 150 0.0000
ARKK 1 Feb 2022 Buy HOOD ROBINHOOD MARKETS INC 66,500 0.0069
ARKK 1 Feb 2022 Sell EDIT EDITAS MEDICINE INC 67,960 0.0102
ARKK 1 Feb 2022 Sell DDD 3D SYSTEMS CORP 73,133 0.0102
ARKK 31 Jan 2022 Buy U UNITY SOFTWARE INC 89,787 0.0798
ARKK 31 Jan 2022 Buy TWLO TWILIO INC 15,803 0.0275
ARKK 31 Jan 2022 Buy TSLA TESLA INC 27,556 0.2193
ARKK 31 Jan 2022 Buy SQ BLOCK INC 39,328 0.0406
ARKK 31 Jan 2022 Sell SKLZ SKILLZ INC 7,482,277 0.3066
ARKK 31 Jan 2022 Buy SE SEA LTD 24,125 0.0309
ARKK 31 Jan 2022 Sell IRDM IRIDIUM COMMUNICATIONS INC 189,796 0.0583
ARKK 31 Jan 2022 Buy HOOD ROBINHOOD MARKETS INC 129,000 0.0145
ARKK 31 Jan 2022 Sell EDIT EDITAS MEDICINE INC 80,005 0.0128
ARKK 31 Jan 2022 Sell DDD 3D SYSTEMS CORP 156,410 0.0233
ARKK 28 Jan 2022 Sell TXG 10X GENOMICS INC 83,970 0.0640
ARKK 28 Jan 2022 Sell SPOT SPOTIFY TECHNOLOGY SA 69,492 0.1060
ARKK 28 Jan 2022 Sell SKLZ SKILLZ INC 1,230,427 0.0469
ARKK 28 Jan 2022 Buy NTLA INTELLIA THERAPEUTICS INC 59,920 0.0431
ARKK 28 Jan 2022 Sell IRDM IRIDIUM COMMUNICATIONS INC 125,192 0.0383
ARKK 28 Jan 2022 Buy HOOD ROBINHOOD MARKETS INC 1,953,643 0.1926
ARKK 28 Jan 2022 Sell DDD 3D SYSTEMS CORP 158,890 0.0229
ARKK 27 Jan 2022 Sell TXG 10X GENOMICS INC 2,944 0.0022
ARKK 27 Jan 2022 Sell TWTR TWITTER INC 194,656 0.0559
ARKK 27 Jan 2022 Buy TSLA TESLA INC 27,799 0.1986
ARKK 27 Jan 2022 Buy NTLA INTELLIA THERAPEUTICS INC 26,278 0.0181
ARKK 27 Jan 2022 Sell IRDM IRIDIUM COMMUNICATIONS INC 48,754 0.0139
ARKK 27 Jan 2022 Sell EDIT EDITAS MEDICINE INC 83,963 0.0133
ARKK 27 Jan 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 989,771 0.0390
ARKK 27 Jan 2022 Sell DDD 3D SYSTEMS CORP 20,700 0.0029
ARKK 26 Jan 2022 Sell SKLZ SKILLZ INC 2,453,465 0.0977
ARKK 26 Jan 2022 Buy NTLA INTELLIA THERAPEUTICS INC 67,772 0.0478
ARKK 26 Jan 2022 Sell EDIT EDITAS MEDICINE INC 1,220,413 0.1948
ARKK 26 Jan 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 895,395 0.0361
ARKK 26 Jan 2022 Sell DDD 3D SYSTEMS CORP 166,623 0.0239
ARKK 26 Jan 2022 Buy CGEN COMPUGEN LTD 7,400 0.0002
ARKK 25 Jan 2022 Sell SKLZ SKILLZ INC 67,732 0.0026
ARKK 25 Jan 2022 Buy PD PAGERDUTY INC 37,389 0.0092
ARKK 25 Jan 2022 Buy NTLA INTELLIA THERAPEUTICS INC 33,900 0.0226
ARKK 25 Jan 2022 Sell EDIT EDITAS MEDICINE INC 113,400 0.0170
ARKK 25 Jan 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 828,483 0.0313
ARKK 25 Jan 2022 Buy CGEN COMPUGEN LTD 32,210 0.0009
ARKK 24 Jan 2022 Sell SKLZ SKILLZ INC 185,981 0.0073
ARKK 24 Jan 2022 Buy PD PAGERDUTY INC 83,725 0.0200
ARKK 24 Jan 2022 Buy NTLA INTELLIA THERAPEUTICS INC 37,515 0.0241
ARKK 24 Jan 2022 Sell EDIT EDITAS MEDICINE INC 231,085 0.0339
ARKK 24 Jan 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 650,644 0.0252
ARKK 24 Jan 2022 Sell DDD 3D SYSTEMS CORP 351,968 0.0465
ARKK 24 Jan 2022 Buy CGEN COMPUGEN LTD 102,100 0.0029
ARKK 21 Jan 2022 Buy VCYT VERACYTE INC 47,300 0.0102
ARKK 21 Jan 2022 Sell TWTR TWITTER INC 815,479 0.2289
ARKK 21 Jan 2022 Buy SSYS STRATASYS LTD 68,424 0.0118
ARKK 21 Jan 2022 Sell SKLZ SKILLZ INC 96,671 0.0038
ARKK 21 Jan 2022 Buy ROKU ROKU INC 103,340 0.1269
ARKK 21 Jan 2022 Buy PD PAGERDUTY INC 185,000 0.0439
ARKK 21 Jan 2022 Sell EDIT EDITAS MEDICINE INC 306,722 0.0452
ARKK 21 Jan 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 597,200 0.0238
ARKK 21 Jan 2022 Sell DDD 3D SYSTEMS CORP 87,600 0.0123
ARKK 21 Jan 2022 Buy COIN COINBASE GLOBAL INC 58,865 0.0908
ARKK 20 Jan 2022 Buy TWOU 2U INC 34,300 0.0044
ARKK 20 Jan 2022 Sell SKLZ SKILLZ INC 1,222,178 0.0558
ARKK 20 Jan 2022 Buy NTLA INTELLIA THERAPEUTICS INC 26,243 0.0180
ARKK 20 Jan 2022 Sell EDIT EDITAS MEDICINE INC 159,694 0.0259
ARKK 20 Jan 2022 Sell DDD 3D SYSTEMS CORP 176,400 0.0268
ARKK 19 Jan 2022 Buy NTLA INTELLIA THERAPEUTICS INC 75,643 0.0511
ARKK 19 Jan 2022 Sell IRDM IRIDIUM COMMUNICATIONS INC 70,681 0.0203
ARKK 19 Jan 2022 Sell EDIT EDITAS MEDICINE INC 188,953 0.0301
ARKK 18 Jan 2022 Buy TWOU 2U INC 75,008 0.0089
ARKK 18 Jan 2022 Buy SSYS STRATASYS LTD 87,600 0.0156
ARKK 18 Jan 2022 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 125,500 0.0106
ARKK 18 Jan 2022 Buy NTLA INTELLIA THERAPEUTICS INC 105,952 0.0697
ARKK 18 Jan 2022 Sell IRDM IRIDIUM COMMUNICATIONS INC 40,713 0.0112
ARKK 18 Jan 2022 Sell IOVA IOVANCE BIOTHERAPEUTICS INC 3,282 0.0004
ARKK 18 Jan 2022 Sell EDIT EDITAS MEDICINE INC 34,263 0.0053
ARKK 18 Jan 2022 Sell DOCU DOCUSIGN INC 212 0.0002
ARKK 18 Jan 2022 Buy CGEN COMPUGEN LTD 27,391 0.0008
ARKK 14 Jan 2022 Sell TSLA TESLA INC 23,398 0.1781
ARKK 14 Jan 2022 Buy TDOC TELADOC HEALTH INC 173,708 0.0999
Latest Blogs
ARK by Cathie Wood is still suffering a year after its apex.

Cathie Wood's flagship exchange-traded fund hit an all-time high in February of this year. Her preferred disruptive-tech chasing strategy may still be in for a lot of suffering after a year and a 53 percent fall.

After a dramatic decline last month, the ARK Innovation ETF (ticker: ARKK) has steadied off - it's practically flat in February – but the headwinds surrounding its speculative growth picks are just becoming more vital. Many businesses that thrived during the pandemic are being hammered by the economic reopening, not only because yields are rising as investors prepare for the US Federal Reserve to raise interest rates, which is terrible news for unprofitable businesses, but also because the economic reopening is hammering many of the businesses that thrived during the pandemic.

Roku, Teladoc, and Zoom, all winners in the work-from-home era, have had their stock prices plummet by as much as 74% in the past year.

Short bets against ARK, according to IHS Markit data, hit a fresh high of 11.4 percent of outstanding shares this week. The Tuttle Capital Short Innovation ETF (SARK), which beats the ARK, now has assets worth more than $US300 million ($416 million).

"Those equities are supported by speculation, and speculation pays less well when the Fed raises rates," said Brent Schutte, chief investment strategist at Northwestern Mutual Wealth Management Co. "Much of what's happening in the market reminds me of what happened in the late 1990s when market segments were bid up to levels based on future assumptions."

Because its price chart resembles that of the Nasdaq index of technology businesses from more than two decades ago, analogies to that period and the dot-com implosion that followed are becoming more common in discussions of ARK.

"Today marks the 253rd trading day from ARK's all-time high," Jessica Rabe, co-founder of DataTrek Research, wrote in a Tuesday note, "while the Nasdaq was down 60% from its dot-com bubble top on the same day in 2001."

"If 2000/2001 analog holds, we should see ARK continuing to fall over the following three weeks. The Nasdaq dropped 18.7% in the next 16 trading days "recent."

Net flows are positive.

The better news for investors and Ms. Wood is that there may be some immediate respite. The Nasdaq rose 41% in six weeks in 2001 before falling.

The ARK Investment Management did not respond to a request for comment.

Most of ARK's $US15 billion asset loss has been attributed to bad performance, a plus for the company. Since the fund achieved an intraday high of $US159.70 a year ago this week, investors have withdrawn only around $US465 million, and ARK's net flows this year are positive despite a more than 20% drop.

This exceptional loyalty prevents a worsening situation and allows Wood's approach to recovering. The star fund manager has consistently emphasized that her funds have a five-year investment horizon and that she believes in many good options.

Mr. Schutte, on the other hand, says the drop is understandable because several of the company's biggest bets, such as Teladoc and Zoom, are becoming less significant as COVID-19 approaches.

"During the pandemic, there were a lot of questions about what would happen to society and how we'd go about our lives," he added.

"You drew in new investors who wanted to know "what are the upcoming themes I should invest in?" I believe you got a washout of it as well."

On Friday, Cathie Wood sold $148.9 million worth of Palantir stock, halving her exposure.

Ark Investment Management, run by Cathie Wood, sold more Palantir Technologies Inc PLTR -6.39 percent shares on Friday, cutting its stake in the Peter Thiel-backed company.

According to Friday's closing price, the famous investment management firm sold 13.5 million shares of the big data company, valued at $148.9 million.

Palantir's stock fell 6.4 percent to $11.02 per share on Friday. The stock has lost 16% of its value in the last week.

Before Friday's trade, Ark Invest held 25.53 million shares in Palantir, suggesting that the famous stock picker had trimmed over 52 percent of its total keeping a day later.

After the business disclosed lower-than-expected fourth-quarter earnings before the market opened on Thursday, Ark Invest, located in St. Petersburg, California, dumped shares in Palantir for the second time.

The software firm, well-known for its work with government organizations, posted earnings of 2 cents per share, falling short of the analyst consensus of 4 cents. The company recorded quarterly revenues of $432.87 million, higher than the $417.69 million predicted by analysts.

Palantir's stock had been sold for 4.77 million shares by the investment firm the day before.

All six of Ark Invest's active exchange-traded funds own Palantir stock, including the flagship Ark Innovation ETF ARKK -4.88 percent.

Before the recent sell-off, Ark Invest had been stockpiling Palantir shares for months.

Cathie Wood appeared on television to defend her ARK funds' dismal performance. It didn't go quite as planned.

The Ark Innovation ETF (ARKK), Cathie Wood's flagship fund, is down 30% year to date and more volatile than almost any other fund on the market. On CNBC's Halftime Report, Wood jumped at the chance to defend the fund and its deflated price, which is currently $68.80, down from $155 a year ago.

"We've seen a significant decline," Wood said, adding, "We feel innovation is at bargain basement zone." Even though her ETF was underperforming, she emphasized that her companies were still "very inexpensive" and that the current fund loss was temporary. When the call's 40 free minutes were finished, Zoom gave her an extra 10 minutes to complete the interview.

Having Zoom check to see whether she was "running out of time?" Wood, who has been aggressively buying up shares in Zoom and other IT firms that have fallen from their pandemic highs, was unhappy. Zoom, like Wood's other significant tech holdings, Teladoc Health, Roku, and Roblox, is down 20% to 40% year to date as investors worry about rising interest and inflation rates.

However, a significant chunk of the interview was devoted to a personal assault on Cathie Wood, who was named the most excellent stock picker in 2020 by Bloomberg's then-Editor-in-Chief Matthew Winkler after correctly forecasting that Tesla will one day be valued at more than $1 trillion.

Wood bluntly ignored Tuttle Capital Management's Short Innovation ETF (SARK), which tracks the inverse performance of ARKK using swaps contracts for the sole purpose of betting against Cathie Wood's selections. "They're not conducting any research." She explained, "All they're doing is shorting innovation."

Of course, SARK is betting against Cathie Woods, not on innovation. "Well, we stand for invention," Wood responded. The SARK ETF has gained 55 percent since its debut, whereas the ARKK ETF has declined by 42 percent.

Tuttle Capital Management CEO Matthew Tuttle chimed in on the SARK ETF, calling it a "tool" for investors. According to SARK, "to convey a negative view of the market, innovative enterprises, the current rising rate environment, or a [specific] portfolio manager if they wish." "It's un-American not to have options in the marketplace," Tuttle told Insider on Thursday.

In any event, Wood is making progress. Her main concern currently is bearish calls on her ETF. "Our major concern is that our investors convert temporary losses into long-term losses," Wood continued.